BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 3785010)

  • 21. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts.
    Buhr T; Georgii A; Schuppan O; Amor A; Kaloutsi V
    Ann Hematol; 1992 Jun; 64(6):286-91. PubMed ID: 1637884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
    Nafe R; Holgado de Colombo S; Choritz H; Georgii A
    Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
    Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
    Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential thrombocythemia.
    Schafer AI
    Prog Hemost Thromb; 1991; 10():69-96. PubMed ID: 2008534
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proplatelet production and stromal fibrosis in myeloproliferative neoplasms.
    Wilkins BS
    Leuk Res; 2010 Nov; 34(11):1417-9. PubMed ID: 20701970
    [No Abstract]   [Full Text] [Related]  

  • 29. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.
    Florena AM; Tripodo C; Di Bernardo A; Iannitto E; Guarnotta C; Porcasi R; Ingrao S; Abbadessa V; Franco V
    J Clin Pathol; 2009 Apr; 62(4):331-8. PubMed ID: 19329711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
    Wolf BC; Neiman RS
    Hematol Oncol Clin North Am; 1988 Dec; 2(4):669-94. PubMed ID: 3065324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Histomorphologic findings of the bone marrow in chronic myeloproliferative diseases].
    Thiele J; Fischer R
    Z Hautkr; 1989 Oct; 64(10):903-4, 909-12. PubMed ID: 2686247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
    Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
    Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
    [No Abstract]   [Full Text] [Related]  

  • 34. [A case of primary myelofibrosis terminating in acute megakaryoblastic leukemia: identification by the demonstration of platelet peroxidase].
    Akahoshi M; Takigawa M; Hagiwara N; Oshimi K; Mizoguchi H; Okada M; Enomoto Y; Watanabe Y; Imai M
    Rinsho Ketsueki; 1984 Mar; 25(3):352-8. PubMed ID: 6088836
    [No Abstract]   [Full Text] [Related]  

  • 35. Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?
    Thiele J; Kvasnicka HM; Diehl V
    Histol Histopathol; 2005 Apr; 20(2):633-44. PubMed ID: 15736066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow fibrosis and diagnosis of essential thrombocythemia.
    Thiele J; Kvasnicka HM; Vardiman JW; Orazi A; Franco V; Gisslinger H; Birgegard G; Griesshammer M; Tefferi A
    J Clin Oncol; 2009 Dec; 27(34):e220-1; author reply e222-3. PubMed ID: 19858378
    [No Abstract]   [Full Text] [Related]  

  • 38. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
    Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
    Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical characterization of essential thrombocythemia in comparison with other myeloproliferative diseases and reactive thrombocytoses].
    Jahn M; Zönnchen B; Köpcke W; Hehlmann R
    Klin Wochenschr; 1988 Mar; 66(5):190-8. PubMed ID: 3163063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.